Capecitabine is an option frequently used in early ABC treatment lines due to its oral availability and favorable toxicity profile; before treatment starting, and to avoid severe, even lethal toxicities an assessment of a potential DPD deficiency by genotyping DPYD gene polymorphisms is recommended [13]. This evidence concerns the gene DPYD and aneurysmal bone cyst.